Genmab A-S
Yahoo Finance • 8 hours ago
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; April 22, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our... Full story
Yahoo Finance • 7 days ago
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
Company Announcement Net sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; Apri... Full story
Yahoo Finance • 12 days ago
Genmab A/S Share Capital Reduction
Company Announcement COPENHAGEN, Denmark; April 10, 2025 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S’ Annual General Meeting on March 12, 2025, it was decided to reduce the Company’s share capital with nominally DKK 2,076,853 by cancellatio... Full story
Yahoo Finance • 15 days ago
Transactions In Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; April 7, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our... Full story
Yahoo Finance • 21 days ago
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Company Announcement COPENHAGEN, Denmark; April 1, 2025 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the t... Full story
Yahoo Finance • 21 days ago
Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts?
We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against other most undervalued healthcare stocks to bu... Full story
Yahoo Finance • 22 days ago
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
Media Release COPENHAGEN, Denmark; March 31, 2025 TIVDAK® is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or after systemic therapyIn the global Ph... Full story
Yahoo Finance • 22 days ago
Transactions in connection with share buy-back program
Company Announcement COPENHAGEN, Denmark; March 31, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our... Full story
Yahoo Finance • 26 days ago
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
Media Release COPENHAGEN, Denmark; March 27, 2025 TIVDAK® is the first and only antibody-drug conjugate (ADC) approved for patients with advanced or recurrent cervical cancer in JapanApproval is based on results from the global Phase 3... Full story
Yahoo Finance • 28 days ago
Genmab Announces Initiation of Share Buy-Back Program
Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billionReduce the capital of Genmab and honor our commitments under the Restricted Stock Unit programCompletion expected no later... Full story
Yahoo Finance • last month
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)Genmab categorically refutes allegations and will vigorously defend the company COPENHAGEN, Denmar... Full story
Yahoo Finance • last month
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
Media Release COPENHAGEN, Denmark; March 17, 2025 Results from Phase 2 RAINFOLTM-01 trial (B1 cohort) showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m2 led to a confirmed objective response rate (ORR) of 55.6%... Full story
Yahoo Finance • last month
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the... Full story
Yahoo Finance • last month
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 12, 2025, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly w... Full story
Yahoo Finance • last month
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical development of HexaBody... Full story
Yahoo Finance • last month
Is Genmab A/S (GMAB) the Best Cash-Rich Undervalued Stock to Invest In?
We recently compiled a list of the 10 Cash-Rich Undervalued Stocks To Invest In.In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other cash-rich undervalued stocks. Currently, big tech and... Full story
Yahoo Finance • 2 months ago
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 614,676 restricted stock units to members of management and employees of the Company as well as the Co... Full story
Yahoo Finance • 2 months ago
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; February 25, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The increase is effected without any preempti... Full story
Yahoo Finance • 2 months ago
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
Media Release COPENHAGEN, Denmark; February 20, 2025 Approval based on results from two Phase 1/2 EPCORE® clinical trials, which demonstrated strong and durable efficacy in patients with relapsed or refractory (R/R) follicular lymphoma... Full story
Yahoo Finance • 2 months ago
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
Media Release COPENHAGEN, Denmark; February 19, 2025 Genmab A/S(Nasdaq:GMAB)announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 45t... Full story
